365413-29-2

Basic information

• Product Name: METHYL 6-CHLORO-5-IODONICOTINATE
• Synonyms: METHYL 6-CHLORO-5-IODONICOTINATE;Methyl 6-chloro-5-iodopyridine-3-carboxylate, 6-Chloro-5-iodo-3-(methoxycarbonyl)pyridine;Methyl 6-chloro-5-iodopyridine-3-carboxylate, 2-Chloro-3-iodo-5-(methoxycarbonyl)pyridine;6-Chloro-5-iodo-3-(methoxycarbonyl)pyridine;6-Chloro-5-iodo-nicotinic acid methyl ester
• CAS NO: 365413-29-2
• Molecular Formula: C₇H₅ClINO₂
• Molecular Weight: 297.48
• Product Categories: Esters;Pyridines
• Mol File: 365413-29-2.mol
• Article Data: 4

Chemical Properties

• Melting Point: 83-85°C
• Appearance: /
• CAS DataBase Reference: METHYL 6-CHLORO-5-IODONICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 6-CHLORO-5-IODONICOTINATE(365413-29-2)
• EPA Substance Registry System: METHYL 6-CHLORO-5-IODONICOTINATE(365413-29-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 365413-29-2(Hazardous Substances Data)

Usage

General Description

Methyl 6-chloro-5-iodonicotinate is a chemical compound with the molecular formula C7H6ClINO2. It is a derivative of nicotinic acid, and its structure consists of a pyridine ring with a methyl group, chlorine atom, and iodine atom attached to different positions on the ring. METHYL 6-CHLORO-5-IODONICOTINATE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It can also act as a building block for the preparation of various organic compounds. Additionally, methyl 6-chloro-5-iodonicotinate has potential applications in medicinal chemistry and drug discovery due to its pharmacological properties and ability to modulate biological processes.

Upstream product

• 885950-46-9 6-hydroxy-5-iodonicotinic acid methyl ester 
• 67-56-1 methanol 
• 365413-19-0 6-hydroxy-5-iodonicotinic acid 
• 66171-50-4 methyl 6-hydroxynicotinate 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 

Downstream Products

• 1361748-71-1 6-chloro-5-(3,4-dichloro-phenyl)-nicotinic acid 
• 1269826-44-9 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide 
• 1373754-96-1 5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinic acid 
• 1361567-63-6 C₁₃H₈Cl₃NO₂ 
• 1346446-87-4 (3,4-dihydro-2H-pyrano[2,3-b]pyridin-6-yl)methanol 
• 73781-91-6 6-Chloronicotinic acid methyl ester 
• 1360952-35-7 methyl 6-chloro-5-(trifluoromethyl)nicotinate 
• 78686-77-8 5-bromo-6-chloro-3-pyridinecarboxylic acid methyl ester 
• 56055-54-0 methyl 2,3-dichloro-pyridine-5-carboxylate 

Relevant articles and documents

Synthesis method of (3,4-dihydro-2H-pyrano[2,3-b]pyridin-6-yl)methanol

The invention discloses a synthesis method of a (3,4-dihydro-2H-pyrano[2,3-b]pyridin-6-yl)methanol compound. Methyl 6-hydroxy-5-iodonicotinate which is used as an initial raw material undergoes a chlorination reaction, and the obtained reaction product and tert-butyl dimethyl(prop-2-alkynyloxy)silane undergo an alkyne substitution reaction, an alkynyl reduction reaction, a TBS protection removal reaction, a cyclization reaction and reduction to obtain the target compound. The synthesis method of the (3,4-dihydro-2H-pyrano[2,3-b]pyridin-6-yl)methanol fills the blank of synthesis methods in theprior art, and the method adopting the above whole synthesis route has the advantages of good step repeatability, high conversion rate, high yield, easiness in purification, mild reaction conditions,high safety, greenness and environmental friendliness; and the obtained 4-fluoro-3-substituted-pyridine-2-formate product compound has the advantages of high purity, good quality, and facilitation ofrealization of industrialization.

PROCESS FOR THE PREPARATION OF NICOTINAMIDE DERIVATIVES

The present invention relates to a process for the preparation of nicotinamide derivatives of formula I, wherein R1 to R7 are as defined above and to pharmaceutically acceptable salts thereof. The compounds of formula I are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of cannabinoid 1 receptors (CB1 receptors) as described in the PCT Publ. WO 2006/106054.